Acanthosis Nigricans

Clinical Snapshot

Acanthosis nigricans (AN) is a skin reaction pattern characterized by symmetric, velvety, hyperpigmented, and thickened plaques, classically affecting the posterior and lateral neck and the axillae, and often extending to the groin and other flexures (antecubital and popliteal fossae, umbilicus, inframammary folds).^[1] Texture, not just colour, defines it: affected skin feels thickened and velvety on palpation, often with a fine, papillomatous surface, and skin tags frequently develop within or at the edge of the plaques.^[2]

The single most important teaching point for this condition is that acanthosis nigricans has no direct topical or systemic cure of its own — it is a cutaneous marker of an underlying process, not a primary skin disease. Correct management means identifying and treating whatever is driving it, not reflexively reaching for a cream. By far the most common driver is obesity-associated insulin resistance, where AN functions as a visible, low-cost flag for undiagnosed prediabetes or type 2 diabetes and should prompt real metabolic screening — arguably the single highest-value action a pharmacist can take on recognizing it.^[3]^[4] A minority of cases are medication-induced, and a rare but critical minority are paraneoplastic (malignant AN), with a distinct presentation that functions as a genuine cancer-screening trigger.^[1] Purely cosmetic topical options exist for patients bothered by residual pigmentation once the underlying cause has been identified and addressed, but these are adjunctive, not the primary intervention, and should never substitute for the metabolic or medication work-up.^[5]

Recognize the Condition

The clinical patterns of acanthosis nigricans

Classic (benign, obesity/insulin-resistance-associated) — by far the most common

Symmetric, velvety, hyperpigmented plaques of the posterior/lateral neck and axillae, often extending to the groin and other flexures. Onset is gradual, over months to years, and severity tracks with the degree of underlying insulin resistance and body weight. Skin tags are common within or adjacent to affected skin. Most patients are otherwise well, and the finding is picked up incidentally on exam rather than volunteered as a complaint.^[1]^[2]

Acanthosis nigricans of the axilla showing velvety, hyperpigmented, thickened skin

Acanthosis nigricans of the axilla — the classic benign, obesity/insulin-resistance-associated presentation, showing the velvety, hyperpigmented, thickened skin texture that defines the condition. (Mark F. Brady & Prashanth Rawla, CC BY-SA 4.0, Wikimedia Commons, via StatPearls/NCBI Bookshelf)

Syndromic

AN accompanying a specific endocrine or genetic syndrome: polycystic ovary syndrome (sometimes as part of HAIR-AN syndrome — hyperandrogenism, insulin resistance, and AN together), severe insulin-resistance syndromes, generalized lipodystrophy, other endocrinopathies (Cushing syndrome, acromegaly, hypothyroidism, Addison disease), and familial AN (autosomal dominant, associated with FGFR3 mutations, presenting earlier in life and sometimes alongside a craniosynostosis syndrome).^[2]

Medication-induced

Clinically identical in appearance to the benign form, but temporally linked to starting a culprit drug and, in many cases, at least partially reversible after stopping it. See Choose Initial Treatment and Drug Tables for the specific agents implicated.^[2]

Malignant (paraneoplastic) — rare, but a genuine red flag

A distinct pattern: rapid onset and progression over weeks to a few months, more extensive and often more pruritic than benign AN, and — the key distinguishing feature — involvement of sites the benign form rarely touches: palms and soles ("tripe palms"), oral and other mucosal surfaces, and periorbital skin. It occurs disproportionately in older adults without the usual obesity/insulin-resistance risk profile, and is most strongly associated with gastrointestinal adenocarcinoma (gastric cancer alone accounts for roughly 60% of cases) as well as genitourinary malignancies.^[1]^[3] See Red Flags & Refer.

Risk Factors

Obesity/overweight — the single strongest risk factor; AN prevalence rises steeply with BMI.
Insulin resistance, prediabetes, and type 2 diabetes — AN is one of the few physical exam findings that reliably flags underlying insulin resistance before it is otherwise diagnosed.^[4]
Polycystic ovary syndrome.
Family history of AN, type 2 diabetes, or insulin resistance.
Black, Hispanic, Indigenous, and South/East Asian populations are disproportionately affected at a given body weight, and AN is frequently under-recognized or dismissed as a normal skin-tone variant in patients with darker skin rather than assessed as a clinical finding — see Special Populations.^[2]
Childhood and adolescent obesity — AN is increasingly seen in children and adolescents in step with rising pediatric obesity rates, and should prompt the same metabolic screening as in an adult.
Use of a medication associated with AN (see Drug Tables).
Other endocrinopathies: Cushing syndrome, acromegaly, hypothyroidism, Addison disease.
Older age combined with a new, rapidly progressive presentation and an otherwise low pretest probability of insulin resistance — a risk factor for the malignant form specifically, not the benign form.

Red Flags & Refer

Most AN is the benign, obesity/insulin-resistance-associated form and belongs in a metabolic work-up, not an urgent referral. Escalate for malignancy assessment instead when any of the following accompany new or changing AN:

Rapid onset or progression over weeks to a few months, rather than the gradual, multi-year course typical of benign AN.^[1]
An older adult (generally over 40) with new AN and no obesity, insulin resistance, or other identifiable benign cause.^[3]
Involvement of the palms and soles ("tripe palms"), oral or other mucosal surfaces, or periorbital skin — sites the benign form essentially never involves.^[1]
Disproportionate pruritus, or unexplained weight loss, anorexia, or other systemic symptoms accompanying the skin change.
Sudden eruption of multiple new seborrheic keratoses alongside the AN (the sign of Leser-Trélat) — another paraneoplastic marker that strengthens the case for a malignancy work-up.^[3]

Any of these findings warrants prompt medical assessment and malignancy work-up (most often directed at gastrointestinal adenocarcinoma) rather than routine obesity-related counselling — malignant AN carries a poor prognosis, so time to diagnosis matters.^[1]

Separately, refer for (non-urgent) dermatology assessment when the diagnosis is genuinely uncertain, when the distribution or texture doesn't cleanly fit AN, or when a biopsy is needed to distinguish AN from a mimicking condition (see Assessment & Diagnosis).

Assessment & Diagnosis

History

Onset and rate of progression — gradual over months to years favours the benign form; rapid progression over weeks favours malignant AN.
Full distribution, explicitly including whether the palms, soles, or oral/mucosal surfaces are involved.
Personal or family history of obesity, type 2 diabetes, prediabetes, PCOS, or other insulin-resistance risk factors.
Complete medication list, including any recently started agent (see Drug Tables).
Unexplained weight loss, anorexia, or other systemic symptoms.
Age — new AN in an older adult without the usual metabolic risk profile carries more weight toward malignancy than the same finding in a younger patient with obesity.

Examination

Confirm the velvety, thickened texture (not just hyperpigmentation) on palpation, document the full distribution, and specifically check the palms, soles, and oral mucosa — a typical benign-pattern exam does not involve these sites, so finding them changes the differential immediately.^[1]

Basic work-up for a typical (benign-pattern) presentation

AN itself is diagnosed clinically; biopsy is reserved for atypical presentations or genuine diagnostic uncertainty.^[2] For a gradual-onset presentation in a patient with obesity or another insulin-resistance risk factor, arrange fasting plasma glucose or A1c (or both, per local practice) and a lipid profile, and screen for PCOS features (menstrual irregularity, hirsutism, acne) where relevant — this work-up is the actual clinical purpose AN exists to trigger.^[4]

Differential diagnosis

Condition	Features that point away from acanthosis nigricans
Confluent and reticulated papillomatosis (Gougerot-Carteaud syndrome)	A reticulated (net-like), rather than confluent velvety, pattern, classically on the trunk/interscapular area; not linked to insulin resistance, and responds to minocycline rather than weight loss or cause-directed therapy.
Pseudo-acanthosis nigricans	Friction- and occlusion-related thickening/pigmentation in obesity without a true underlying insulin-resistance or endocrine driver; often improves with weight loss alone, but is a diagnosis of exclusion.
Dowling-Degos disease	A genetic reticulate pigmentary disorder — a comb-like/reticulate pigmentation pattern rather than confluent velvety plaques, and lacks the metabolic association.
Terra firma-forme dermatosis	Dirt-like brown plaques that wipe off completely with firm alcohol-swab rubbing — a simple bedside test that excludes AN.
Addison disease / other diffuse hyperpigmentation	Diffuse, flat hyperpigmentation (including palmar creases, mucosa, sun-exposed skin) rather than the localized, velvety, thickened flexural plaques of AN.
Tinea versicolor	Fine scale on gentle scraping and KOH-positive hyphae/spores, with a trunk-predominant rather than flexural distribution.
Dermatosis papulosa nigra	Discrete small pigmented papules, typically on the face, rather than confluent velvety plaques.
X-linked ichthyosis	Generalized fine, dark scale rather than flexural, velvety thickening; presents from infancy in males.

Treatment Targets

Identify and treat the specific underlying cause — this is the actual treatment target, not clearing the skin directly.
In obesity/insulin-resistance-associated AN: achieve meaningful weight loss and improved glycemic control, and formally diagnose and manage any prediabetes or type 2 diabetes uncovered by screening.
In medication-induced AN: discontinue or substitute the culprit agent where clinically appropriate, in consultation with the prescriber.
In malignant AN: achieve prompt cancer diagnosis and treatment — skin improvement follows successful tumour treatment and is not pursued as an independent goal.
Reduce flexural maceration, malodour, and the risk of secondary bacterial or fungal infection in affected skin folds.
Only once the underlying cause is identified and being addressed: offer realistic, adjunctive cosmetic improvement in pigmentation/texture to patients who are bothered by appearance.

Choose Initial Treatment

Direct treatment rule

Step 1 — determine the driver before treating anything

Acanthosis nigricans is not treated empirically. Use the history, exam, and basic work-up above to place the patient into one of 3 buckets — obesity/insulin-resistance-associated, medication-induced, or (rarely) malignant/paraneoplastic — before choosing a management path; treating the skin in isolation without this step is the single most common error in AN management.

Step 2 — obesity/insulin-resistance-associated AN (the great majority of cases)

1st line confirm the metabolic driver with fasting glucose or A1c (and a lipid profile), start structured weight-management counselling/lifestyle intervention, and involve the prescriber for metformin or other diabetes-specific pharmacotherapy if prediabetes or type 2 diabetes is confirmed on screening — metformin's benefit here is entirely through improving the underlying insulin resistance, not a direct effect on the skin.^[3]^[4]

If PCOS is suspected (menstrual irregularity, hirsutism, acne alongside the AN), work up and manage per the Polycystic Ovary Syndrome chapter.

Step 3 — medication-induced AN

Review with the prescriber whether the culprit medication (see Drug Tables) can be discontinued or switched, weighing that decision against the indication it is being used for — this is a shared decision with the prescriber, not something to stop unilaterally. Skin changes typically begin to improve over weeks to months once the causative agent is withdrawn, though resolution is often partial.^[2]

Step 4 — malignant (paraneoplastic) AN

Urgent referral for malignancy work-up (see Red Flags & Refer) rather than any skin-directed treatment. Skin findings improve with successful treatment of the underlying tumour and can recur with tumour recurrence — the AN itself is a marker to track, not a target to treat directly. Cyproheptadine is sometimes used as an adjunct for associated pruritus while oncologic treatment proceeds.^[1]

Step 5 — cosmetic-only topical options, once the cause is addressed

Not a substitute for Steps 1-4 offer only to a patient who remains bothered by visible pigmentation/texture after the underlying cause has been identified and is being actively addressed. See Pharmacologic Treatment Options and Drug Tables for specific agents; set the expectation up front that response is gradual, often partial, and these agents do nothing for the underlying condition.^[5]

Non-Pharmacologic Treatment

Structured weight-management support (dietitian referral, physical activity counselling) — the single most effective non-drug intervention for obesity/insulin-resistance-associated AN; improvement in the skin itself typically lags well behind weight loss and glycemic improvement.
Skin-fold hygiene: keep affected flexures clean and dry, favour breathable fabrics, and gently pat rather than vigorously rub the area to limit friction-related worsening.
Address malodour or maceration promptly, since thickened, occluded flexural skin is prone to secondary bacterial or yeast overgrowth.
Set realistic expectations from the first visit: even with the underlying cause fully addressed, pigmentation and texture often improve slowly, over months, and may only partially resolve — this is the expected course, not a treatment failure.
Skin tags associated with AN can be removed for comfort or cosmetic reasons (cryotherapy or snip excision by a clinician) — this addresses the skin tag, not the AN itself.

Pharmacologic Treatment Options

There is no drug that treats acanthosis nigricans itself. The table below separates genuine cause-directed pharmacotherapy (used to treat the underlying insulin resistance or paraneoplastic pruritus, not the skin) from purely cosmetic topical options, which are adjunctive and should only be offered once the underlying cause has been identified and addressed.

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Metformin Preferred	Cause-directed — confirmed prediabetes or type 2 diabetes	Per the Diabetes Mellitus chapter; titrate under prescriber direction	GI upset; rare lactic acidosis in significant renal impairment	Treats the underlying insulin resistance driving the skin change; has no direct effect on AN itself.
Cyproheptadine Special situation	Adjunct for pruritus in paraneoplastic (malignant) AN	Per product directions, low-dose antihistaminic use	Sedation, anticholinergic effects	Symptom adjunct only while oncologic treatment of the underlying malignancy proceeds — not a treatment for the AN itself.
Tretinoin, topical Preferred	Cosmetic-only, once the cause is addressed	Apply once daily at bedtime, per product directions; expect a gradual response over months	Local irritation, dryness, photosensitivity; avoid in pregnancy	Strongest evidence among cosmetic topical options (grade A recommendation in a 2024 systematic review) — a cosmetic adjunct only, not a substitute for cause-directed management.
Adapalene, topical Alternative	Cosmetic-only alternative retinoid	Apply once daily, per product directions	Local irritation, dryness	Generally better tolerated than tretinoin; an alternative cosmetic option with supporting trial evidence.
Salicylic acid, topical Alternative	Cosmetic keratolytic adjunct	Apply per product directions	Local irritation, stinging	Softens thickened, hyperkeratotic plaques; used alongside a topical retinoid, not instead of cause-directed management.
Calcipotriol, topical Alternative	Cosmetic-only alternative	Apply per product directions	Local irritation; hypercalcemia with excessive use	Less commonly used than the topical retinoids; a further cosmetic option in refractory cases.
Oral (systemic) retinoids / other systemic therapy for cosmetic clearing Avoid	Not indicated for cosmetic AN management	Not applicable	Significant systemic toxicity (teratogenicity, hepatic, and lipid effects, depending on agent)	The systemic toxicity burden is never justified for a purely cosmetic indication — do not use.

Special Populations

Pregnancy

AN can worsen during pregnancy because of the physiologic insulin resistance of later pregnancy — this is expected and, on its own, is not a new diagnostic concern, but it reinforces the need for routine gestational diabetes screening per standard obstetric protocol rather than a separate work-up. Avoid topical retinoids (tretinoin, adapalene) in pregnancy given teratogenicity concerns with the retinoid class; use salicylic acid and calcipotriol cautiously and only if genuinely needed, weighing benefit against limited safety data. Defer purely cosmetic treatment to the postpartum period where possible.

Breastfeeding

Data on topical retinoids in lactation are limited; given the purely cosmetic indication, it is reasonable to defer cosmetic topical therapy until breastfeeding has ended rather than accept an avoidable, unknown-risk exposure.

Pediatrics and adolescents

AN in a child or adolescent living with obesity is an important, and increasingly common, trigger for the same prediabetes/type 2 diabetes screening recommended in adults — do not dismiss it as a benign incidental finding at this age.^[4] Early-onset, unusually extensive AN — especially with a family history or coexisting skeletal/craniofacial features — should raise suspicion for a familial (FGFR3-associated) syndrome and prompt genetics referral rather than routine obesity counselling alone.^[2]

Skin of colour

AN is disproportionately common, and disproportionately under-recognized, in patients with darker skin tones — the velvety texture and thickening can be mistaken for a normal variant of skin pigmentation rather than assessed as a clinical finding warranting metabolic screening. Actively palpate and examine flexural skin in at-risk patients rather than relying on visual impression alone, and apply the same screening threshold regardless of skin tone.^[2]

Monitoring & Follow-Up

What to monitor depends entirely on which bucket the patient is in.

Obesity/insulin-resistance-associated AN

Track weight, waist circumference, and glycemic parameters (A1c or fasting glucose) on the same schedule used for prediabetes/type 2 diabetes monitoring; expect skin improvement to lag well behind metabolic improvement, and to be gradual and often partial even with sustained weight loss.

Medication-induced AN

Reassess the skin at a follow-up visit after the culprit agent is discontinued or substituted; improvement typically begins over weeks to months.

Malignant (paraneoplastic) AN

Follows the oncology treatment/surveillance schedule. Skin changes generally improve with successful tumour treatment and are a useful, low-cost bedside marker to watch for tumour recurrence.

Cosmetic topical therapy (if used)

Reassess at 3 months for early tolerability/irritation and again at 6 months for response; keep reinforcing that this is adjunctive and the cause-directed plan remains the priority regardless of cosmetic outcome.

Treatment Failure / Next Step

Confirm the diagnosis is genuinely AN and not a mimicking condition (see Assessment & Diagnosis) — a persistent, unchanged plaque that never responds to any intervention should prompt reconsideration of confluent and reticulated papillomatosis, pseudo-acanthosis nigricans, or another differential rather than escalating AN-directed therapy further.
Confirm the presumed cause was actually addressed — was the metabolic work-up completed and acted on, was the culprit medication genuinely stopped (not just planned to be stopped), and has enough time passed (months, not weeks) for skin improvement to plausibly show?
If a clear driver was addressed adequately and the skin still hasn't improved after a reasonable interval, widen the differential — screen more broadly for an occult endocrinopathy, or, in a patient with the relevant risk profile (older age, disproportionate/rapid course, mucosal or palm/sole involvement), reconsider malignant AN even if it wasn't the leading concern initially.
If cosmetic topical therapy specifically was tried without adequate response after a full 3-6 month trial, consider combination cosmetic therapy or referral for a procedural option (e.g., fractional CO2 laser, chemical peel) — but continue to frame this as optional and adjunctive.
Persistent diagnostic uncertainty at any point warrants dermatology referral, including biopsy if not already performed.

Common Errors to Avoid

Reaching for a topical cream before working up the underlying cause — the cream is never the primary intervention.
Assuming AN in an older adult is automatically the benign, obesity-related form without actively checking for the malignant-pattern red flags (rapid onset, palm/sole/mucosal involvement, disproportionate pruritus).
Not screening a child or adolescent with new AN for prediabetes/type 2 diabetes because "they're too young."
Dismissing AN in a patient with darker skin as a normal pigmentation variant rather than examining and assessing it as a clinical finding.
Not reviewing the medication list for a culprit drug before assuming the AN must be obesity-related.
Overpromising cosmetic outcomes — even successful cause-directed treatment often leaves residual pigmentation for a long period, and patients should be told this up front.
Using systemic therapy purely for cosmetic skin clearing — the toxicity is never justified for this indication.
Confusing AN with confluent and reticulated papillomatosis, which looks superficially similar but is a completely different condition, unrelated to insulin resistance and treated with minocycline rather than weight loss or metabolic therapy.

Clinical Decision Algorithm

Algorithm A — Recognize acanthosis nigricans and triage for malignancy red flags

Suspected acanthosis nigricans: symmetric, velvety, hyperpigmented, thickened plaques (neck, axillae, groin, or other flexures)

Assess onset/rate of progression, full distribution (including palms, soles, and oral/mucosal surfaces), age, pruritus, weight/obesity status, medication list, and personal/family history of diabetes, prediabetes, or PCOS

Rapid onset, palm/sole/mucosal involvement, disproportionate pruritus, unexplained weight loss, or an older adult without obesity/insulin-resistance risk factors

Malignant (paraneoplastic) AN suspected — refer urgently for malignancy work-up (most often gastrointestinal adenocarcinoma); do not default to routine obesity-related management

Diagnosis uncertain, or distribution/texture atypical

Consider biopsy or dermatology referral to confirm AN and exclude a mimicking condition (see Assessment & Diagnosis)

Gradual onset, classic distribution, consistent with obesity/insulin resistance, a known culprit medication, or a recognized syndrome

Proceed to Algorithm B — cause-directed management

Algorithm B — Cause-directed management

Benign-pattern AN confirmed; likely cause identified

Obesity/insulin-resistance-associated (most common)

Screen with fasting glucose or A1c and a lipid profile; start weight-management counselling/lifestyle intervention; involve the prescriber for metformin or diabetes-specific therapy if prediabetes/T2DM is confirmed

Medication-induced

Review the culprit drug (see Drug Tables) with the prescriber; discontinue or substitute where clinically appropriate, weighing this against the drug's own indication

Syndromic (PCOS/HAIR-AN, other endocrinopathy, familial)

Direct work-up/referral to the specific underlying condition — the PCOS pathway, endocrinology, or genetics for suspected familial AN

Reassess the skin over months once the underlying cause is being actively addressed; set the expectation that improvement is gradual and often partial

Patient remains bothered by residual pigmentation/texture

Proceed to Algorithm C — cosmetic-only topical options

Cause resolving or resolved and patient not bothered by appearance

No AN-specific treatment needed — continue routine monitoring of the underlying condition

Algorithm C — Cosmetic-only topical options

Underlying cause identified and being actively addressed; patient requests cosmetic improvement

Counsel explicitly that these options treat only the visible skin change, not the underlying condition, and that response is gradual over months and often partial

Topical tretinoin once daily (preferred; strongest evidence) or adapalene once daily (alternative); add a salicylic acid or calcipotriol adjunct if needed; consider laser referral for an inadequate response after a full trial

Cosmetic response is never urgent — cause-directed management (Algorithm B) remains the priority regardless of how the skin responds

Drug Tables

How to use this table: Doses are adult doses unless a separate pediatric line is given, and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Culprit medications (can cause or worsen AN)

A drug appearing here is not automatically a reason to stop it — review with the prescriber, weighing the drug's own indication against the AN it may be driving. Not an exhaustive list.

Drug	Dosage / relevance	Adverse effects	Drug interactions	Comments
Niacin (nicotinic acid)	Relevance to AN: Well-documented culprit, particularly at high (lipid-modifying) doses	Flushing, hepatotoxicity at high dose; AN with prolonged high-dose use	None specific to AN	One of the best-documented culprit drugs for medication-induced AN, particularly at the high doses once used for dyslipidemia.
Systemic corticosteroids	Relevance to AN: AN can develop with prolonged systemic use	Hyperglycemia, weight gain, osteoporosis, adrenal suppression with prolonged use	None specific to AN	Contributes to AN partly through corticosteroid-induced insulin resistance; consider alongside other steroid-stewardship measures.
Combined oral contraceptives	Relevance to AN: Uncommon but reported culprit	Venous thromboembolism risk, breast tenderness, nausea	None specific to AN	An uncommon cause; consider a non-hormonal or lower-dose alternative with the prescriber if temporally linked.
Growth hormone (somatropin)	Relevance to AN: Direct insulin-antagonist effect can drive AN	Insulin resistance, edema, arthralgia	None specific to AN	AN can develop through growth hormone's direct insulin-antagonist effect.
Protease inhibitors	Relevance to AN: Class effect via insulin resistance/lipodystrophy	Insulin resistance, dyslipidemia, GI upset	Potent CYP3A4 inhibitor with an extensive interaction list	Insulin resistance and lipodystrophy are well documented with this drug class; AN can accompany either.
Injected (high-dose) insulin	Relevance to AN: Reported with very high-dose/concentrated regimens	Hypoglycemia, lipohypertrophy at injection sites	None specific to AN	Very high insulin doses/concentrations, as in severe insulin-resistance states, can themselves drive AN — a reminder that insulin resistance, not insulin itself, is the underlying driver.
Aripiprazole	Relevance to AN: Reported culprit among atypical antipsychotics	Akathisia, weight gain, extrapyramidal symptoms	None specific to AN	A more recently reported culprit — consider if AN develops after starting an atypical antipsychotic with no other clear driver.

Cause-directed pharmacotherapy

Treats the underlying insulin resistance or paraneoplastic symptom, not the skin itself.

Drug	Dosage / relevance	Adverse effects	Drug interactions	Comments
Metformin	Use in AN: Indirect — treats the confirmed underlying insulin resistance/T2DM	GI upset (dose-related), rare lactic acidosis in significant renal impairment	None major for this indication	First-line pharmacologic option once prediabetes or type 2 diabetes is confirmed on screening; see the Diabetes Mellitus chapter for full dosing and titration.
Cyproheptadine	Use in AN: Symptom adjunct only, paraneoplastic pruritus	Sedation, anticholinergic effects, weight gain	Additive CNS depression with other sedating agents	Adjunct for pruritus in paraneoplastic (malignant) AN while oncologic treatment of the underlying tumour proceeds — does not treat the AN itself.

Cosmetic-only topical options

Offer only once the underlying cause has been identified and is being actively addressed; none of these agents treat the underlying condition, and response is gradual, often over several months, and frequently partial.

Drug	Dosage / relevance	Adverse effects	Drug interactions	Comments
Tretinoin, topical	Dosing: Apply once daily at bedtime, per product directions	Local irritation, dryness, photosensitivity	None clinically significant with topical use	Strongest evidence among cosmetic options — a 2024 systematic review of AN treatment trials gave topical tretinoin its strongest (grade A) recommendation. Avoid in pregnancy.
Adapalene, topical	Dosing: Apply once daily, per product directions	Local irritation, dryness	None clinically significant with topical use	Generally better tolerated than tretinoin; an alternative retinoid with supporting trial evidence (grade B). Avoid in pregnancy.
Salicylic acid, topical	Dosing: Apply per product directions	Local irritation, stinging	None clinically significant with topical use	Keratolytic adjunct that softens thickened plaques; used alongside a topical retinoid rather than as monotherapy.
Calcipotriol, topical	Dosing: Apply per product directions	Local irritation; hypercalcemia with excessive use over a large body-surface area	None clinically significant with limited topical use	A further cosmetic option in refractory cases; less commonly used than the topical retinoids.

Not indicated for cosmetic AN clearing

Listed to state explicitly that these should not be used purely for cosmetic skin clearing, not as routine options.

Drug	Dosage / relevance	Adverse effects	Drug interactions	Comments
Oral (systemic) retinoids	Use in AN: Not recommended for cosmetic clearing	Teratogenicity, hepatotoxicity, dyslipidemia, mucocutaneous toxicity	Numerous — extensive interaction profile depending on the specific agent	The systemic toxicity burden is never justified for a purely cosmetic indication — use only if independently indicated for another diagnosis.

References

Acanthosis Nigricans — StatPearls, NCBI Bookshelf (Brady MF, Rawla P). StatPearls Publishing, Treasure Island (FL), 2024
Acanthosis Nigricans — DermNet NZ (Ida JA; original: Ngan V; updated: Haroon A; reviewed by Coulson I). DermNet NZ, updated March 2025
Common Hyperpigmentation Disorders in Adults: Part II. Melanoma, Seborrheic Keratoses, Acanthosis Nigricans, Melasma, Diabetic Dermopathy, Tinea Versicolor, and Postinflammatory Hyperpigmentation — American Family Physician (Stulberg DL, Clark N, Tovey D). Am Fam Physician 2003;68(10):1963-1969
Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome — Diabetes Canada Clinical Practice Guidelines Expert Committee (Punthakee Z, Goldenberg R, Katz P). Can J Diabetes 2018;42(Suppl 1):S10-S15
Systematic review of topical, laser, and oral treatments in acanthosis nigricans clinical trials — Archives of Dermatological Research (Bitterman D, Patel P, Zafar K, et al.). Arch Dermatol Res 2024;316(7):424

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.